Abstract
OLIKOS Study: 6-month Interim Efficacy and Safety in Patients with Relapsing Multiple Sclerosis Who Switched to Subcutaneous Ofatumumab from Intravenous Anti-CD20 Therapies (P10-6.006)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have